PVmed and RADLogics Announce Strategic Partnership to Advance AI-Powered Medical Imaging Solutions

Recently, Guangzhou PVmed Medical Technology Co., Ltd. (hereinafter referred to as “PVmed”) has officially entered into a strategic partnership with RADLogics, an AI medical imaging workflow manufacturer based in Silicon Valley, USA. The two parties will join hands to carry out comprehensive, long-term cooperation in areas such as resources, market expansion, technology, and internationalization, jointly pioneering a new landscape of AI-empowered medical imaging.

PVmed, established in May 2017, is a pioneer and technology provider in medical artificial intelligence. Despite being a startup, its multiple technologies in the field of AI-assisted diagnosis and treatment based on medical imaging have risen to a leading level both domestically and internationally within just three years.

“AI Serving Healthcare” is the founding mission of PVmed; therefore, the company’s core business focuses on the research, development, and sales of AI-assisted diagnostic and therapeutic software for medical imaging, along with related technical services. It provides hospitals and third-party medical institutions with comprehensive, multi-disease, multi-modal AI-assisted diagnostic and therapeutic solutions.

All products developed by PVmed are independently researched and developed. Among them, the Intelligent Delineation System for Radiotherapy Target Volumes in Nasopharyngeal Carcinoma is a global first. The Medical Image Transmission and Processing Software has obtained a Class II Medical Device Registration Certificate. Other products, including the Medical Image Processing System, the Pulmonary Nodule Computer-Aided Diagnosis System, and the Rib Suppression-Assisted Reading System, have completed research and development and entered the stages of clinical pilot application and market promotion. Products such as the Intelligent Delineation System for Radiotherapy Target Volumes have been trialed at top-tier hospitals both domestically and internationally, including the Sun Yat-sen University Cancer Center, Sichuan Cancer Hospital, and the National Cancer Centre Singapore, receiving unanimous acclaim from industry experts.

“It has become an industry consensus that AI will deeply penetrate multiple clinical application scenarios in medical imaging.” Commenting on this collaboration, Lu Yao, Chairman of PVmed, stated, “In the face of technological transformation and clinical demands, PVmed is joining forces with RADLogics to fully leverage their respective strengths. Together, they will explore safer, smarter, and more efficient AI-powered medical imaging solutions, drive the intelligent and digital transformation of radiology departments, enable high-quality medical resources and services to reach more patients, and jointly build a new ecosystem for healthcare.”

RADLogics, founded in 2010, is an AI medical imaging company based in Silicon Valley, USA. It primarily develops medical imaging software for radiology departments, providing fully automated AI medical imaging solutions to help radiologists improve work efficiency and ultimately enhance patient treatment outcomes. The company has R&D laboratories in Boston, USA, and Tel Aviv, Israel. As one of the pioneers in medical image analysis, RADLogics leverages advanced big data analytics, artificial intelligence, and machine learning to perform quantitative analysis on massive volumes of medical image data from CT, MRI, PET, and X-ray scans. Through automated detection and structured report generation, it reduces diagnostic turnaround time from hours to minutes.

Moshe Becker, founder of RadLogics, is a seasoned technology entrepreneur with 25 years of business experience spanning international engineering, healthcare IT, mobile communications, marketing management, and enterprise solutions. His co-founder and Chief Scientist, Hayit Greenspan, is a professor in the Department of Biomedical Engineering at Tel Aviv University and an affiliated researcher at the Computer Science Division of the University of California, Berkeley. As one of the earliest professors globally to conduct research on deep learning in medical imaging, she has garnered high acclaim within the industry.

As an early pioneer, RADLogics has accumulated the most professional and advanced algorithm development tools and collaborates with several leading global OEM distribution partners, including Nuance, a company capable of rapidly deploying artificial intelligence solutions in international markets. After more than a decade of development, RADLogics has deployed its medical imaging AI solutions worldwide, having analyzed and processed millions of CT and X-ray scans for hospitals in the United States, Russia, China, and India.

Commenting on the strategic partnership with PVmed, Moches Becker, Founder and CEO of RADLogics, stated, “As pioneers in artificial intelligence and machine learning technologies, this strategic collaboration between PVmed and RADLogics will enable both parties to further expand their presence in the Asian market and enhance the capabilities of clinicians and radiologists in medical imaging diagnosis. More importantly, our early work and research on AI-assisted detection and analysis for COVID-19 were conducted in China, which aligns closely with the objective of this partnership: to provide healthcare workers and clinicians with novel tools during the post-pandemic recovery period, thereby alleviating resource strains on regional healthcare systems.”

RADLogics’ AI software incorporates a variety of algorithms that not only detect abnormalities in chest CT and X-ray images but also automatically triage and prioritize cases based on disease severity, ensuring that radiologists can provide timely and appropriate examination and treatment. Furthermore, these AI-based tools can perform quantitative analysis on lung CT or X-ray images of patients suspected of having COVID-19, generating relevant numerical scores to enable healthcare professionals to conduct comparative analyses of examinations performed at different time points. In response to the COVID-19 pandemic, RADLogics has allocated dedicated resources for diverse clinical settings, modifying its algorithms and deployment strategies to adapt to various environments, thereby facilitating the rapid detection of lung abnormalities associated with COVID-19. This tool played a critical role as an auxiliary screening aid during the global outbreak of the pandemic this year.

Coincidentally, PVmed also took immediate action at the onset of the pandemic by launching an AI-assisted screening system for COVID-19, efficiently and safely supporting disease diagnosis and clinical management.

In fact, as early as 2018, PVmed and RadLogics had already engaged in discussions regarding their respective technologies and products.

After more than two years of in-depth understanding and development discussions, both parties have formally established a cooperative relationship. The strategic partnership between PVmed and RadLogics is not only a collaboration of technologies but also an integration of business cultures, with both sides reaching a consensus on dual empowerment through technology and branding.

Shen Shuo, CEO of PVmed, stated: “After years of development, validation, and refinement, AI-driven medical products are steadily entering clinical practice to serve physicians and patients, thanks to the joint efforts of clinicians, regulatory bodies for registration and testing, and commercial enterprises. This sector has entered a phase of accelerated growth both in China and in other international markets. Given the long development cycles and regionally concentrated resource requirements characteristic of the medical device industry, collaboration among healthcare companies is particularly crucial across capital, market, and solution dimensions. PVmed is committed to partnering with companies like RadLogics that possess internationally leading technologies and extensive long-term expertise, aiming to achieve mutual success and breakthroughs in multiple fields.”

It is well known in the industry that a significant portion of medical data originates from medical imaging. While the volume of medical imaging data continues to grow year by year, the growth rate and work efficiency of radiologists are insufficient to keep pace with this trend, placing immense pressure on physicians. Currently, the majority of medical imaging data still requires manual analysis, the most prominent drawback of which is imprecision; judgments based solely on clinical experience are prone to misdiagnosis.

The development of artificial intelligence technology offers a novel approach to addressing the challenges facing contemporary medical imaging. With rapid algorithmic breakthroughs and continuously growing computational power in the field, AI is gradually surpassing the visual limits of radiologists, delivering diagnostic reports faster and more accurately. “AI-empowered medical imaging” serves as an effective solution for this domain.

Both PVmed and RadLogics are AI medical imaging companies deeply committed to this field. Guided by clinical needs, both aim to integrate imaging and AI technologies, collaborate closely with radiologists and clinicians, and develop practical, high-value products for physicians.

In this initiative, PVmed and RadLogics have forged a deep partnership closely aligned with their core industrial strategic layouts. By leveraging their respective resource advantages and driven by technological innovation, the two companies will focus on R&D innovation, commercialization of scientific achievements, and market-oriented promotion and application, jointly propelling the substantial development of AI in medical imaging.